<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856359</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00093318</org_study_id>
    <nct_id>NCT03856359</nct_id>
  </id_info>
  <brief_title>Trial of Rifaximin in Probable Alzheimer's Disease</brief_title>
  <official_title>Pilot, Single Center, Open, Trial of Rifaximin in Probable Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to improve cognition and function in patients with Alzheimer's Disease (AD)&#xD;
      by administering the oral antibiotic, Rifaximin.&#xD;
&#xD;
      Rifaximin is a virtually non-absorbed antibiotic with the unique properties of lowering blood&#xD;
      ammonia levels and altering gut microbiota. It is FDA approved for use in patients with&#xD;
      hepatic encephalopathy. Rifaximin lowers blood ammonia by altering fecal flora by blocking&#xD;
      bacterial RNA synthesis and also by increasing small bowel glutaminase. The Investigators&#xD;
      hypothesize that rifaximin will improve cognition and function in AD patients by lowering&#xD;
      blood ammonia and / or lowering circulatory pro-inflammatory cytokines secreted by harmful&#xD;
      gut bacteria. The Investigators will enroll up to 10 subjects with probable middle stage&#xD;
      Alzheimer's Disease. The subjects will be given rifaximin 550 mg orally twice daily for 3&#xD;
      months after evaluation to ensure they have no contraindications. Physician clinical and&#xD;
      safety assessments, adverse events, as well as the ADAS-Cog-11 will be administered at&#xD;
      baseline and at the 3 month endpoint and two months after stopping treatment (at month 5).&#xD;
      Interim safety checks will occur via phone calls one week after baseline and then every 2&#xD;
      weeks till end point. Serum neuronal biomarkers, ammonia levels and pro-inflammatory and&#xD;
      anti-inflammatory compounds will also be measured at those times. Bodily fluids (Stool&#xD;
      samples) will also be collected. Because of a small risk of developing C. difficile up to 2&#xD;
      months following the last administration of rifaximin, the subjects will be followed for an&#xD;
      additional 2 months after the 3 month treatment ends.&#xD;
&#xD;
      Rifaximin is contraindicated in patients with hypersensitivity to rifaximin or rifamycin&#xD;
      antimicrobials. Hypersensitivity reactions include exfoliative dermatitis, angioneurotic&#xD;
      edema, and anaphylaxis. Clostridium difficile associated diarrhea is a risk whenever a&#xD;
      patient is maintained chronically on antibiotics, with complications ranging from mild&#xD;
      diarrhea to fatal colitis. Drug resistant bacteria can also result from long term use. There&#xD;
      is increased systemic exposure to rifaximin in patients with severe hepatic impairment or in&#xD;
      patients who are taking P-glycoprotein inhibitors concomitantly. Regarding use in geriatric&#xD;
      patients, there were no reported overall differences in the safety of the drug when used in&#xD;
      patients 65 years of age or over, when compared with younger subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to improve cognition and function in patients with Alzheimer's Disease (AD)&#xD;
      by administering the oral antibiotic, rifaximin. Rifaximin is a virtually non-absorbed&#xD;
      antibiotic with the unique properties of altering gut microbiota and lowering blood ammonia&#xD;
      levels. It is FDA approved for use in patients with hepatic encephalopathy. Rifaximin lowers&#xD;
      blood ammonia by blocking gut bacterial RNA synthesis and also by increasing small bowel&#xD;
      glutaminase. The Investigators hypothesize that rifaximin will improve cognition and function&#xD;
      in AD patients by mechanisms such as lowering circulatory pro-inflammatory cytokines secreted&#xD;
      by harmful gut bacteria or lowering blood ammonia.&#xD;
&#xD;
      Rifaximin is a relatively gut-specific antibiotic that interferes with by binding to the&#xD;
      transcription subunit of bacterial . Because Rifaximin is absorbed poorly, most of the drug&#xD;
      taken RNA polymerase orally stays in the gastrointestinal tract. It has been available since&#xD;
      2004 in the US and has orphan gastrointestinal tract drug status for hepatic encepalopathy.&#xD;
      Rifaximin's relatively good safety profile and its ability to alter gut flora and lower blood&#xD;
      ammonia have made it an attractive drug to treat hepatic encephalopathy or conditions such as&#xD;
      traveller's diarrhea. The Investigators hypothesize that rifaximin will improve cognition and&#xD;
      function in AD patients by mechanisms such as lowering circulatory pro-inflammatory cytokines&#xD;
      secreted by harmful gut bacteria or lowering blood ammonia.&#xD;
&#xD;
      The Investigators will measure a variety of blood markers, such as pro-inflammatory and&#xD;
      anti-inflammatory compounds, and analyze fecal microbiota in patients with AD before and&#xD;
      after 3 months of rifaximin therapy. If patients exhibit measurable improvement in cognition&#xD;
      and function, The Investigators will analyze our data to see if their improvement correlates&#xD;
      with a shift towards anti-inflammatory species in the gut and a similar shift in the blood&#xD;
      cytokine panel to favoring anti-inflammatory compounds.&#xD;
&#xD;
      Evidence supporting our hypothesis for this study is presented below.&#xD;
&#xD;
      Gut Microbiota Dysbiosis&#xD;
&#xD;
      The gut harbors 95% of the total human microbiome and is made up of more than 5,000 taxa. Gut&#xD;
      species remain relatively constant throughout adulthood until the seventh decade, when it&#xD;
      becomes less diverse, harboring higher numbers of Proteobacteria and lower numbers of&#xD;
      Bifidobacteria. An imbalance in the gut bacterial species can weaken the intestinal barrier&#xD;
      and create system wide inflammation via gut lymphoid tissue which comprises 70% - 80% of the&#xD;
      immune system. Blood brain barrier permeability is also altered. The gut bacteria secrete&#xD;
      pro-inflammatory compounds and neuroactive molecules that include serotonin,&#xD;
      gamma-aminobutyric acid (GABA), catecholamines and acetylcholine which cross the blood brain&#xD;
      barrier and cause brain inflammation and brain dysfunction.&#xD;
&#xD;
      A growing number of pro-inflammatory compounds secreted by gut bacteria and seen in patients&#xD;
      with AD are being discovered. These include interleukin (IL) - 6, tumor necrosis - alpha and&#xD;
      the inflammasome complex (NLRP3). A recent study revealed higher numbers of Escherichia and&#xD;
      Shigella in the gut of amyloid positive AD patients when compared with healthy controls and&#xD;
      this correlated with higher levels of circulating pro-inflammatory cytokines. The AD patients&#xD;
      also had lower numbers of gut Eubacterium rectale and this correlated with lower levels of&#xD;
      circulating anti-inflammatory compounds than seen in controls. Other researchers found that a&#xD;
      preponderance of gut Bacteroides and Blautia and reduced numbers of SMB53 and Dialister&#xD;
      correlated with elevated levels of brain amyloid Cerebrospinal Fluid (CSF) biomarkers.&#xD;
      Interestingly, Clostridium tyrobutyricum and Bacteroides thetaiotaomicron, have been shown to&#xD;
      actually increase the integrity of the blood brain barrier by enhancing expression of tight&#xD;
      junction proteins and helping to maintain brain homeostasis. Recent evidence also suggests&#xD;
      that neurotransmitters and neuropeptides secreted by bacteria in the gut activate vagal nerve&#xD;
      ascending fibers, influencing brain function.&#xD;
&#xD;
      Ammonia Neurotoxicity&#xD;
&#xD;
      A second theory is that the blood brain barrier allows greater amounts of ammonia into the AD&#xD;
      brain, triggering or worsening pre-existent changes. The possibility that ammonia is at least&#xD;
      partly responsible for the pathologic changes seen in the AD brain was first proposed by&#xD;
      Seiler in 1993, when he noted that some of the changes in the AD brain can also be seen in&#xD;
      the brains of hyperammonemic patients. Arteriovenous sampling in early stage normoammonemic&#xD;
      AD patients demonstrated higher endogenous cortical ammonia compared to young control&#xD;
      subjects Low glutamine synthetase levels have been found to correlate with increased density&#xD;
      of amyloid deposits in the AD brain.&#xD;
&#xD;
      The brain also receives exogenous ammonia, of which the gut is a major source. The aging&#xD;
      colon contains a greater percentage of protein fermenting bacteria than is seen in the colon&#xD;
      of younger patients.&#xD;
&#xD;
      Rifaximin lowers blood ammonia by altering fecal flora by blocking bacterial RNA synthesis&#xD;
      and also by increasing small bowel glutaminase.&#xD;
&#xD;
      The Investigators hypothesize that Rifaximin will improve cognition and function in AD&#xD;
      patients by lowering circulatory pro-inflammatory cytokines secreted by harmful gut bacteria&#xD;
      and / or lowering blood ammonia levels. The subjects will be given rifaximin 550 mg orally&#xD;
      twice daily for 3 months after evaluation to ensure they have no contraindications. Physician&#xD;
      clinical and safety assessments, adverse events, as well as the ADAS-Cog11 will be&#xD;
      administered at baseline and at the 3 month endpoint. Interim safety checks will occur via&#xD;
      phone calls one week after baseline and then every 2 weeks till 3 month end point. Serum&#xD;
      neuronal biomarkers, ammonia levels and pro-inflammatory and antiinflammatory compounds will&#xD;
      also be measured at those times. Bodily fluids (Stool samples) will also be collected.&#xD;
      Because of a small risk of developing C. difficile up to 2 months following the last&#xD;
      administration of rifaximin, the subjects will be followed for an additional 2 months after&#xD;
      the 3 month treatment ends.&#xD;
&#xD;
      This is an open label pilot study designed to provide preliminary evidence on the clinical&#xD;
      efficacy of rifaximin in improving cognition in AD patients. The Investigators will be&#xD;
      looking for improvement in test scores and changes in serum levels of neuronal markers,&#xD;
      circulating cytokine pro-inflammatory compounds and colonic microbiota following treatment.&#xD;
      The Investigators will also be collecting data regarding the safety of long term use of this&#xD;
      non-absorbed antibiotic for this disease. This pilot may form the basis for a future larger&#xD;
      randomized, double blind controlled study to further test this hypothesis.&#xD;
&#xD;
      The rifaximin dosage and route of administration are the same as that used to treat hepatic&#xD;
      encephalopathy, for which the drug and dosage are FDA approved. The dose will remain the same&#xD;
      throughout the 3 month study of rifaximin administration unless stopped for safety reasons.&#xD;
      The age and study sample of mild to moderate probable AD is similar to that used in AD prior&#xD;
      trials. The Investigators will select our sample to be medically stable and free of hepatic&#xD;
      disease and not having had recent antibiotic therapy to minimize risk for C Difficile&#xD;
      infection.&#xD;
&#xD;
      The end of the study will occur 5 months after baseline testing and first administration of&#xD;
      the drug. While drug administration will conclude and endpoint testing will be done at 3&#xD;
      months, The Investigators will continue to follow each subject for an additional 2 months, as&#xD;
      C. difficile infectious diarrhea can occur up until 2 months after stopping an antibiotic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Actual">November 19, 2020</completion_date>
  <primary_completion_date type="Actual">November 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-COG)</measure>
    <time_frame>Change from baseline global cognitive scores at month 3. Global cognitive performance assessed by a psychometrician using (ADAS-Cog).</time_frame>
    <description>Done at Baseline, 3 month and 5 month visits. ADAS-Cog is a widely used cognitive endpoint in AD clinical trials and changes on this scale, over time, are considered clinically meaningful. ADAS-11 range is 0-70 with higher scores indicating worse performance. Errors from 11 items are added to generate the total score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>5 months</time_frame>
    <description>Collected at every visit and follow-up phone visits. A rare side effect of Rifaximin is diarrhea caused by clostridium difficile. This is a very serious form of diarrhea that can be fatal if not treated. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum neuronal markers</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Done at Baseline, 3 month and 5 month visits. When brain tissue is damaged, it releases substances (serum neuronal markers) into the blood, such as Neurofilament Light. The investigators will be looking for the amount of these serum neuronal markers to decrease after three months of Rifaximin treatment, indicating less brain tissue damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum pro-inflammatory markers</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>The investigators will be looking for changes in the amounts of the following pro-inflammatory markers:&#xD;
Interleukin (IL) 1 beta, IL 2, IL 4, IL 5, IL 6, IL 8, IL 10, IL 13, Tumor necrosis factor - alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiota</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>The study drug, Rifaximin, is an antibiotic. It changes the mixture of bacteria in the colon. The investigators will analyze the types of bacteria that are in the patient's colon. The microbiome variables the investigators will use standard FDR correction to examine nominal significance of change from baseline. The investigators will be assessing the Escherichia, shigella, pseudomonas, bacteroides, eubacterium and Faecalibacterium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tolerability as measured by number of Adverse Events (AE).</measure>
    <time_frame>Baseline, 3 months, 5 months</time_frame>
    <description>Assessed at every visit. The patients will be followed closely to see if they are tolerating the drug, Rifaximin. The of the number of side effects would indicate that the patient may not be tolerating the drug. Most of these side effects are minor and include headache, nausea, vomiting, tiredness. A potentially fatal side effect would be the development of clostridium difficile diarrhea. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance on the Mini-Mental State Exam (MMSE)</measure>
    <time_frame>Assessed at screening and month 3</time_frame>
    <description>Change from baseline global cognitive scores at month 3). Global cognitive performance will be assessed by a psychometrician using the (MMSE). It is a brief cognitive questionnaire with a maximum score of 30 points. MMSE range is 0-30 with lower scores indicating worse performance. The number of correct answers is added to generate the total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Safety measures as measured by treatment emergent AEs as reported by the subject</measure>
    <time_frame>Safety will be measured through adverse events throughout study at month 3 and by phone call at month 5 (2 months after treatment termination).</time_frame>
    <description>Safety will be measured through adverse events as reported by the subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Complete Blood Count (CBC)</measure>
    <time_frame>Safety will be measured through labs at screening and at month 3.</time_frame>
    <description>Clinically significant deviations from the baseline on CBC will be considered an AE and clinically significant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>Safety will be measured through labs at screening and at month 3.</time_frame>
    <description>Clinically significant deviations from baseline to month 3 in blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pulse</measure>
    <time_frame>Safety will be measured through labs at screening and at month 3.</time_frame>
    <description>Clinically significant deviations from baseline to month 3 in pulse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Chemistry values</measure>
    <time_frame>Safety will be measured through labs at screening and at month 3.</time_frame>
    <description>Clinically significant deviations from the baseline on Chemistry values as defined as Creatine, blood urine nitrogen, electrolytes and sodium potassium chloride results will be considered an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Liver Function Test (LFT) will be measured by ALT and AST lab results from baseline</measure>
    <time_frame>Safety will be measured through labs at screening and at month 3.</time_frame>
    <description>Clinically significant deviations from the baseline on LFT will be considered an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in C Difficile infection</measure>
    <time_frame>Safety will be measured through labs at screening and at month 3.</time_frame>
    <description>Clinically significant deviations from the baseline on clinically significant and newly emergent C Difficile infection will be considered.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rifaximin 550 milligrams (mg) orally twice daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin 550 milligrams (MG)</intervention_name>
    <description>Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.</description>
    <arm_group_label>Rifaximin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Â· Probable Alzheimer's Disease (National Institute of Neurological Disorders and&#xD;
             Stroke (NINDS) criteria), mild to moderate severity&#xD;
&#xD;
               -  Ages 55-85; both genders&#xD;
&#xD;
               -  Mini Mental State Exam (MMSE) scores 10-23&#xD;
&#xD;
               -  Willing and able to comply with all scheduled clinic visits.&#xD;
&#xD;
               -  Stable medical health&#xD;
&#xD;
               -  Has a family or professional caregiver who has regular contact with subject&#xD;
&#xD;
               -  Ability to consent or legal guardian who can consent&#xD;
&#xD;
               -  Living at home or in a facility&#xD;
&#xD;
               -  On no AD therapies or on stable (2 months) concurrent AD therapies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past history of C diff infection&#xD;
&#xD;
          -  Assessment, laboratory examination, physical examination or any other medical&#xD;
             condition or circumstance making the volunteer unsuitable for participation in the&#xD;
             study in the judgment of the study clinicians&#xD;
&#xD;
          -  Allergy to Rifaximin&#xD;
&#xD;
          -  Antibiotic use or hospitalization in the last 6 months&#xD;
&#xD;
          -  Are taking medications that interact with rifaximin and/or pose a safety risk in the&#xD;
             judgment of the PI&#xD;
&#xD;
          -  Clinically significant abnormal hepatic or renal function&#xD;
&#xD;
          -  Uncorrected thyroid or B12 abnormalities&#xD;
&#xD;
          -  Participation in another investigational drug trial in the past 30 days&#xD;
&#xD;
          -  History of febrile illness within 5 days prior to the study period&#xD;
&#xD;
          -  Known Hyperammonemia caused by:&#xD;
&#xD;
        Valproic acid Chemotherapy Lung transplant Bariatric surgery Ureterosigmoidoscopy&#xD;
        Hyperalimentation Urinary tract infection Errors of metabolism: urea cycle, enzyme&#xD;
        deficiencies, organic acidemias, fatty acid oxidation, amino acid transport defects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Suhocki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 18, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

